In the Checkmate 227 study, the first line treatment by two immune checkpoint inhibitors (Nivolumab plus Ipilimumab) showed a significantly longer progression free survival on the tumor mutational burden positive patient (≥10 mutations/Mb) independent of PD-L1 expression in advanced non-small-cell lung cancer [48]. Here, CD274 is linked to non-small cell lung carcinoma.